10-Q: Dror Ortho-Design Q2 2026 Update: Development Continues Amidst Financial Challenges

Dror Ortho-Design reports continued development of its orthodontic platform, with reduced R&D spending, but faces significant going concern doubts due to ongoing losses and reliance on financing.

Summary

• Dror Ortho-Design, Inc. filed its Form 10-Q for the quarter ended June 30, 2026.
• The company is in the development stage of an AI-based orthodontic alignment platform and has not yet generated material revenues.
• Research and development expenses decreased by 53% to $150,769 for the three months ended June 30, 2026, compared to $324,068 in the prior year period.
• General and administrative expenses decreased by 12% to $344,997 for the three months ended June 30, 2026.
• The company reported a net loss of $625,143 for the three months ended June 30, 2026, and $1,263,809 for the six months ended June 30, 2026.
• As of June 30, 2026, the company had cash of $93,563 and a negative working capital of $3,751,932, raising substantial doubt about its ability to continue as a going concern.
• The company received $575,000 in bridge loans during the first six months of 2026, compared to $500,000 in the same period of 2025.
• The company plans to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant ongoing losses, a precarious cash position, and substantial doubt about the company's ability to continue as a going concern, despite some cost reductions.

Positives

• Reduced research and development expenses by 53% to $150,769 for Q2 2026, indicating potential cost management in development activities.
• Decreased general and administrative expenses by 12% to $344,997 for Q2 2026, suggesting improved operational efficiency.
• Secured $575,000 in financing through bridge loans in the first six months of 2026, providing some liquidity.
• The company has several patents for its technology and is preparing its prototype for FDA approval.

Negatives

• The company has not yet generated material revenues and continues to incur significant operating losses.
• Net loss for the three months ended June 30, 2026, was $625,143, and $1,263,809 for the six months ended June 30, 2026.
• Cash balance of $93,563 as of June 30, 2026, with negative working capital of $3,751,932, leading to substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on external financing and there is no assurance of successful capital raises.
• The company's orthodontic platform requires new 510(k) clearance from the FDA, which has not yet been filed.
• Significant debt discount amortization ($236,787 for six months ended June 30, 2026) due to convertible promissory notes and associated derivative liabilities.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient resources to fund operations for the next twelve months.
• The company is in the development stage, has no operating history in manufacturing and distribution, and its products may not be accepted by consumers.
• The company faces competition from large, internationally established aligner companies.
• Failure to obtain necessary FDA authorizations for the platform could adversely affect the ability to grow the business.
• The company's success depends on its proprietary technology, and failure to enforce intellectual property rights could harm its competitive position.
• The company is subject to risks associated with the ongoing war in Israel, although current R&D activities remain largely unaffected.
• The company may need to delay, reduce, or eliminate certain programs, sell assets, or merge if it cannot raise sufficient capital.

Future Outlook

The company intends to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection. However, it anticipates continued operating losses and is dependent on raising additional capital to fund operations and growth.

Management Comments

• Management believes that recent rapid advancements in technology have made traditional aligner solutions no longer the most effective treatment option for smile correction.
• Management believes that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions; rather, they can get a perfect smile discreetly and hassle-free even while they sleep with our FDA-cleared proprietary solution.
• Management has substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance of these unaudited condensed consolidated financial statements.
• Management does not believe that inflation has had a material impact on the Company's business, sales, or operating results during the periods presented.

Industry Context

StockSavvy.ai notes that Dror Ortho-Design is operating in the highly competitive orthodontic aligner market, which is dominated by established players. The company's proposed AI-based, sleep-time aligner solution aims to differentiate itself from traditional, all-day wear aligners, but faces significant hurdles in FDA approval and market acceptance.

Comparison to Industry Standards

• The company's R&D spending of $150,769 for the quarter is significantly lower than established medical device companies, reflecting its early-stage development.
• The company's net loss of $625,143 for the quarter is typical for pre-revenue medical device startups but highlights the need for substantial future funding.
• The company's reliance on bridge financing is a common strategy for early-stage companies but carries higher interest costs and dilution risks compared to traditional debt or equity rounds.

Legal Proceedings

• As of the date of filing, the company is not a party to any material litigation, nor is it aware of any threatened or pending litigation.

Related Party Transactions

• Accrued executive salaries of $239,539 as of June 30, 2026, were unpaid due to cash management considerations.
• A director, Yehuda Englander, receives a monthly cash fee of $2,500 plus expense reimbursements for consulting services, totaling $12,200 for Q2 2026 and $23,499 for the first six months of 2026.

Stakeholder Impact

• Shareholders face continued dilution risk due to ongoing reliance on equity and debt financing and the potential for further capital raises.
• Creditors and noteholders face uncertainty regarding the repayment of convertible promissory notes and debentures due to the company's going concern issues.
• Employees may face uncertainty regarding job security if the company cannot secure sufficient funding to continue operations.

Next Steps

• File for 510(k) clearance for the Platform with the FDA.
• Continue software and hardware development.
• Seek additional equity or debt capital to fund operations.
• Protect intellectual property associated with software and hardware projects.

Key Dates

Recommendation

The company is in a highly speculative, pre-revenue stage with significant going concern risks. While development continues and cost controls are being implemented, the lack of revenue and substantial doubt about continued operations warrant a cautious 'hold' recommendation until a clear path to commercialization and sustainable funding is established.

Keywords

orthodontic alignment platform, AI-based solution, FDA clearance, medical device development, startup financing, going concern, convertible notes, derivative liability